4D Molecular Therapeutics (FDMT) Stock Price, News & Analysis

$24.25
-0.56 (-2.26%)
(As of 04/24/2024 ET)
Today's Range
$24.23
$25.38
50-Day Range
$24.25
$35.87
52-Week Range
$9.44
$36.25
Volume
290,423 shs
Average Volume
1.05 million shs
Market Capitalization
$1.24 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$44.22

4D Molecular Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.4% Upside
$44.22 Price Target
Short Interest
Bearish
18.22% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of 4D Molecular Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$4.07 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.03) to ($3.15) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

Medical Sector

379th out of 907 stocks

Biological Products, Except Diagnostic Industry

55th out of 154 stocks

FDMT stock logo

About 4D Molecular Therapeutics Stock (NASDAQ:FDMT)

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

FDMT Stock Price History

FDMT Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
A new way to collect income from stocks
Most people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively…
4D Molecular Therapeutics Inc (FDMT)
4DMT to Participate in Upcoming Investor Conferences
See More Headlines
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
4/24/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FDMT
Fax
N/A
Employees
147
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$44.22
High Stock Price Target
$81.00
Low Stock Price Target
$24.00
Potential Upside/Downside
+82.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
10 Analysts

Profitability

Net Income
$-100,840,000.00
Net Margins
-436.30%
Pretax Margin
-486.60%

Debt

Sales & Book Value

Annual Sales
$20.72 million
Book Value
$7.20 per share

Miscellaneous

Free Float
45,683,000
Market Cap
$1.24 billion
Optionable
Optionable
Beta
2.87
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. John F. Milligan Ph.D. (Age 63)
    Executive Chairman
    Comp: $150k
  • Dr. David H. Kirn M.D. (Age 62)
    Co-Founder, CEO & Director
    Comp: $920.97k
  • Dr. Fariborz Kamal Ph.D. (Age 61)
    President & COO
    Comp: $678.4k
  • Dr. Noriyuki Kasahara M.D. (Age 61)
    Ph.D., Chief Scientific Officer
    Comp: $13.6k
  • Ms. Theresa Janke (Age 49)
    Co-Founder & Chief of Staff
    Comp: $652.32k
  • Mr. Uneek Mehra (Age 52)
    Chief Financial & Business Officer
  • Dr. Scott P. Bizily J.D. (Age 51)
    Ph.D., Chief Legal Officer & Corporate Secretary
  • Dr. Robert Y. Kim M.B.A. (Age 63)
    M.D., Chief Medical Officer
  • Dr. An Song Ph.D.
    Chief Development Officer
  • Dr. Alan H. Cohen FAAAAI (Age 63)
    FAAP, FACAAI, FCCP, M.D., Senior VP & Therapeutic Area Head of Pulmonology

FDMT Stock Analysis - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last twelve months. There are currently 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" FDMT shares.
View FDMT analyst ratings
or view top-rated stocks.

What is 4D Molecular Therapeutics' stock price target for 2024?

10 analysts have issued twelve-month price targets for 4D Molecular Therapeutics' stock. Their FDMT share price targets range from $24.00 to $81.00. On average, they expect the company's stock price to reach $44.22 in the next year. This suggests a possible upside of 82.4% from the stock's current price.
View analysts price targets for FDMT
or view top-rated stocks among Wall Street analysts.

How have FDMT shares performed in 2024?

4D Molecular Therapeutics' stock was trading at $20.26 at the beginning of the year. Since then, FDMT stock has increased by 19.7% and is now trading at $24.25.
View the best growth stocks for 2024 here
.

Are investors shorting 4D Molecular Therapeutics?

4D Molecular Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,320,000 shares, an increase of 9.6% from the March 15th total of 8,500,000 shares. Based on an average daily volume of 1,170,000 shares, the short-interest ratio is currently 8.0 days.
View 4D Molecular Therapeutics' Short Interest
.

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our FDMT earnings forecast
.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) released its quarterly earnings results on Thursday, February, 29th. The company reported ($0.77) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.09. The company had revenue of ($0.02) million for the quarter, compared to the consensus estimate of $4.67 million. 4D Molecular Therapeutics had a negative trailing twelve-month return on equity of 34.14% and a negative net margin of 436.30%.

What ETFs hold 4D Molecular Therapeutics' stock?
When did 4D Molecular Therapeutics IPO?

4D Molecular Therapeutics (FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager.

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.84%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include David Kirn, David Schaffer, Global Investors Lp Viking, Jacob Chacko, Robert Young Kim and Scott Bizily.
View institutional ownership trends
.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FDMT) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners